The overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy.
Patients with advanced EGFR-mutated NSCLC who were given osimertinib plus chemotherapy up front continue to show improved outcomes after initial progression, suggests ongoing trial data.
New research supports the use of highly effective therapies as first-line treatment in children with relapsing-remitting pediatric-onset multiple sclerosis.